tiprankstipranks
MeiraGTx Holdings Reports Promising Parkinson’s Therapy Results
Company Announcements

MeiraGTx Holdings Reports Promising Parkinson’s Therapy Results

The latest announcement is out from Meiragtx Holdings ( (MGTX) ).

Don't Miss our Black Friday Offers:

MeiraGTx Holdings has unveiled promising results from its clinical bridging study of AAV-GAD, a gene therapy for Parkinson’s disease, showcasing significant improvements in both motor function and quality of life. The study demonstrated an 18-point average improvement in motor scores for the high dose group and noted meaningful enhancements in patient-reported outcomes, with no serious adverse events reported. This progress paves the way for a potential Phase 3 trial, aiming to position AAV-GAD as a groundbreaking treatment for Parkinson’s globally.

For a thorough assessment of MGTX stock, go to TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskMeiraGTx Holdings Reports Significant Losses Amid Strategic Moves
TheFlyMeiraGTx reports Q3 EPS (55c) vs (74c) last year
TheFlyMeiraGTx announecs five posters at ESGCT 2024 Annual Congress
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App